The Cholestatic Liver Disease Consortium (CLiC) is now part of ChiLDREN , the Childhood Liver Disease Research and Education Network. The new and expanded network combines CLiC and the Biliary Atresia Research Consortium (BARC), as well as new studies on cystic fibrosis liver disease. This consolidation seeks to facilitate the discovery of new diagnostics, etiologic, and treatment options for children with rare liver diseases, and those who undergo liver transplantation, and to train the next generation of investigators in rare pediatric liver diseases.
Restriction enzymes, such as Eco RI, are used in a wide variety of molecular genetics techniques including cloning , DNA screening and deleting sections of DNA in vitro . Restriction enzymes, like Eco RI, that generate sticky ends of DNA are often used to cut DNA prior to ligation , as the sticky ends make the ligation reaction more efficient. Eco RI can exhibit non-site-specific cutting, known as star activity , depending on the conditions present in the reaction. Conditions that can induce star activity when using Eco RI include low salt concentration, high glycerol concentration, excessive amounts of enzyme present in the reaction, high pH and contamination with certain organic solvents. 
Cerebrotendinous xanthomatosis (CTX) is an autosomal recessive genetic disorder due to mutations in the sterol 27-hydroxylase gene ( CYP27A1 ), resulting in a deficiency of the mitochondrial enzyme sterol 27-hydroxylase. The lack of this enzyme prevents cholesterol from being converted into a bile acid called chenodexoycholic acid. Lipid rich deposits containing cholestanol and cholesterol accumulate in the nerve cells and membranes, and cause damage to the brain, spinal cord, tendons, lens of the eye and arteries. Affected individuals experience cataracts during childhood and benign, fatty tumors (xanthomas) of the tendons during adolescence. The disorder leads to progressive neurologic problems in adulthood such as paralysis, ataxia and dementia. Coronary heart disease is common. More than 300 patients with CTX have been reported to date worldwide and about 50 different mutations identified in the CYP27A1 gene. Almost all mutations lead to the absent or inactive form of the sterol 27-hydroxylase. Dietary therapy with the bile acid, chenodeoxycholic acid, does correct many of the symptoms of CTX; however, early diagnosis of the disorder with early therapy leads to a better clinical outcome. The activity of cholesterol 7 alpha-hydroxylase, the rate limiting enzyme in bile acid synthesis, is normalized by this diet therapy and there is a reduction in the development of xanthomas.